# Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects

> **NCT00848211** · PHASE1,PHASE2 · COMPLETED · sponsor: **Thymon, LLC** · enrollment: 24 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** TUTI-16 (0.03mg)
- **BIOLOGICAL:** TUTI-16 (0.1mg)
- **BIOLOGICAL:** TUTI-16 (0.6mg)

## Key facts

- **NCT ID:** NCT00848211
- **Lead sponsor:** Thymon, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00848211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00848211, "Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00848211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*